Efficacy and safety of finerenone in non-diabetic CKD patients: a single-center, real-world, retrospective study.

In patients with other glomerulopathies (Henoch-Schönlein purpura nephritis, minimal change nephropathy, etc.), the UACR a declining trend over the 12-month follow-up period, but this reduction did not reach statistical significance when compared to baseline measurements ( P > 0.05), as shown in Supplemental Fig. 3 .

also in 111,027 other papers

In the IgA nephropathy subgroup, UACR demonstrated a decreasing trend within the 12-month follow-up; however, this decrease was not statistically significant compared to baseline ( P > 0.05).

also in 47,180 other papers